California Oncology Weekly
"An Oncologists’ Source for Timely Information"
A publication of the
Medical Oncology Association of Southern California, Inc.
March 2, 2021
|
|
-
MOASC welcomes 3 new physicians to the Board of Directors MOASC News
-
Tomorrow, March 3, Pfizer-BioNTech COVID-19 Vaccine webinar. MOASC News
-
Thursday, March 4, Enhertu presentation. Industry News
|
|
MOASC Programs - Save the Dates - All Times are Pacific
|
|
March 3, 2021, at 5:30pm MOASC Members are encouraged to attend the “Pfizer-BioNTech COVID-19 Vaccine” webinar, with Michael Dutro, PharmD, Vaccines Medical Director, California, New Mexico, Hawaii, Pfizer Biopharma, presenting. (Pharma reps are not allowed in this presentation)
|
|
MOASC’S Annual Oncology Summit virtual webinar, Exciting Advances in Oncology, will be presented on Saturday, March 27, 7:00 am - 1:00 pm (PST). Please join us for a virtual presentation by nationally recognized speakers, that will follow a multi-tumor approach, reviewing current management strategies and recent advances in Breast cancer, Colorectal-Genitourinary cancers, Thoracic cancer and Lymphoma. This will be a great opportunity to learn from experts and network with colleagues. This event is free to all those interested in attending.
|
|
The California Assembly health Committee held an informational hearing last week looking at Telehealth Policy in California Post-Pandemic. The purpose of the hearing was to begin discussing which telehealth policy changes made during the pandemic should be made permanent. DHCS argued that although their proposal did not maintain all flexibilities or telephonic/asynchronous coverage for federally qualified health centers, it did maintain telephonic/asynchronous coverage for individual practitioners, just not at parity, reflecting what they thought was a more reasonable and balanced approach. The public comment portion of the hearing included providers and patient groups, called in to voice their support of telehealth and concern with Medi-Cal potentially not maintaining telephonic payment parity protections for all providers post-pandemic.
|
|
Noridian News
The 2020 1099-INT and 1099-MISC are now available on the Noridian Medicare Portal (NMP). The 1099 inquiry is available through the Financials function.
|
|
CMS News
The Centers for Medicare & Medicaid Services (CMS) reminds all Medicare Promoting Interoperability Program participants that the deadline to submit 2020 data is April 1, 2021 at 8:59 PM PT. Medicare Promoting Interoperability Program participants are required to register and attest through the QualityNet Secure Portal.
|
|
The Centers for Medicare & Medicaid Services (CMS) National Standards Group (NSG) has released a new Administrative simplification fact sheet detailing the savings the health care industry could achieve by conducting fully electronic eligibility and benefits inquiry and response transactions.
|
|
UnitedHealthcare has published their March 2021 updated bulletins on:
Oncology Supportive Care Medication Sourcing Requirement; Radiation Therapy Prior Authorization; Medical Policy; Reimbursement Policy; Specialty Medical Injectable Drug Program, and more.
|
|
The Leukemia & Lymphoma Society (LLS) is pleased to announce the opening of the Susan Lang Pre CAR T-cell Therapy Travel Assistance Program. This program provides financial assistance to patients diagnosed with a blood cancer who are being evaluated to receive CAR T-cell therapy as either standard treatment or a clinical trial.
|
|
Affiliate Association News |
|
ANCO News
21st Multidisciplinary Management of Cancers meeting to be held March 12-14, 2021. The 2021 program represents a collaborative effort of expert clinicians from the Stanford Cancer Institute, University of California, Davis, University of California, San Francisco, and the Association of Northern California Oncologists. The program will be held virtually.
|
|
ASH News
Registration is Open for the 2021 Highlights of ASH Series. This year’s all-virtual experience will take place March 1 – April 2, 2021 and feature program curated annual meeting content derived from all four regions ASH has historically presented in: North America, the Mediterranean, Asia-Pacific, and Latin America.
|
|
The virtual ASCO Annual Meeting is scheduled for June 4-8, 2021. Register now for the best rates. The early registration deadline is April 28, 2021 at 8:59 PM (PT).
|
|
COA News
Please contact COPA right away if your practice has received a notice from Anthem that requires white bagging or filling specialty drugs through CVS in various practice and outpatient settings. Currently, we are aware of letters sent by Anthem to practices in California, Indiana, Ohio and Tennessee. It is believed that Anthem will continue to expand this policy to other states. If your practice received one of these notices, it is important that you reach out to Anthem right away, and inquire how you can be admitted back into Anthem as a specialty pharmacy to continue to administer and treat your patients the same way you have always done. COA leadership met with Anthem last year and were told that practices are to reach out to Anthem to determine next steps to allow you to continue to operate as you had in the past.
|
|
Do not miss the 2021 Community Oncology Conference, April 8 & 9, 2021. See community oncology from a new perspective. This year’s, free, virtual-conference is so much more than just best-in-class educational programs. Not only does the Conference offer unmatched opportunities to hear from key players in the field of oncology, but more importantly, the content is focused on the needs of independent, community oncology practices. Learn about social determinants of health and how other practices are incorporating this data into their workflow. Economics greatly affect how care is provided and successful patient outcomes. Get a deeper understanding of how oncology care can address the community’s needs. There’s something for every member of community oncology, so bring a large contingent from your practice!
|
|
Oncopeptides announced that the FDA has approved PEPAXTO® (melphalan flufenamide, also known as melflufen, in combination with dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma, who have received at least four prior lines of therapy and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one CD38-directed monoclonal antibody.
|
|
AstraZeneca cordially invites MOASC Members to their upcoming Enhertu Advanced Gastric Broadcast Presentation. The program will discover a new indication for Enhertu and how it may help certain patients with unmet need. On March 4, 2021 at 3:30PM PST and 5:30PM PST.
|
|
Agios Pharmacuticals presents three Virtual Disease Awareness webinars on Pyruvate Kinase Deficiency: An Under recognized Cause of Chronic Hemolytic Anemia on March 23rd, 31st and April 8th.
|
|
Incyte Corporation invites your patients to attend any four of their live webinars about myeloproliferative neoplasms (MPN). These disease education virtual talks are geared for patients diagnosed with a myeloproliferative neoplasm (MPN), including: Polycythemia vera, Essential thrombocythemia, Myelofibrosis. The program on 4/28 includes a nutrition talk and MPN. Hear from an Incyte Oncology Clinical Nurse Educator about MPNs, learn and ask questions about your condition. You will receive a workbook of the presentation in the mail to help you organize your thoughts. When you register, Incyte will send you a kit with a workbook, educational resources, and accessories to help raise awareness about MPNs. Have questions or want to register? Register today through any of the below most convenient for you.
919-256-2479
|
|
The Medical Oncology Association of Southern California (MOASC) is a leading oncology society that advances and protects the ability of cancer patients to obtain, and the ability of the oncology physicians to provide, optimal cancer care. The material contained in the California Oncology Weekly is intended as general information for MOASC members. Because diagnostic, treatment, contracting, coding, and billing decisions should be made on a case-by-case basis, any such information contained in the California Oncology Weekly may not apply in any given situation. Members are encouraged to contact their own consultants or advisors to obtain specific advice on matters relating to contracting, coding, and billing. The information contained in California Oncology Weekly should not be used as a substitute for such advice. This publication provides a summary of regulations affecting oncology and its business practices. Reading this newsletter does not substitute for understanding regulations and verifying the validity of every claim. This information is time-sensitive and is subject to change. MOASC accepts no liability for any statements or articles herein. CPT codes are owned and trademarked by the American Medical Association. All Rights Reserved.
|
|
|
|
|
|
|
